Firma ProtaGene, Autor bei Presse-Blog

New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets

22. November 2023 Firma ProtaGeneAllgemeinampersand, analytics, biologics, biosimilars, cell, cmc, cro, discovery, disease, gene, lab, patients, protagene, research, therapy

ProtaGene, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, today announced additional investment from Ampersand Capital Partners. Given the critical importance of advanced bioanalytics and product characterization for developing increasingly Mehr

Confronting Molecular Bioanalysis Challenges in Gene Therapy Development

19. Oktober 202322. Oktober 2023 Firma ProtaGeneAllgemeinassay, cell, clinical, cmc, development, gene, genomics, pcr, regualtory, therapy

As the gene therapy sector continues to mature, regulators’ expectations for more robust product understanding are growing. It’s exciting to be part of today’s gene therapy development community; however, three issues are at the top of the industry’s mind—the regulatory Mehr

Navigating CMC Challenges in NBE and Therapeutic Antibody Development

11. September 202311. September 2023 Firma ProtaGeneAllgemeinantibody, Biotech, bipharma, development, drug, mab, pharma, protagene, research, therapy

In April 2021, the FDA approved the 100th monoclonal antibody as a therapeutic entity, a milestone that took 35 years to reach. As of the fall of 2022, the FDA has approved 162 antibody therapies, and approval momentum continues to Mehr

ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy Innovators

1. Februar 20231. Februar 2023 Firma ProtaGeneAllgemeinbioanalytix, cell, cmc, genewerk, indigo, labcorp, market, new, patients, protagen, protagene, research, therapy, thermo, with

ProtaGene GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, announced today the appointment of Jennifer Chadwick, Ph.D., as Chief Scientific Officer and Owen Hitchins as Chief Commercial Officer. Working in Mehr

Foundation for the Industry’s Next-stage Innovation and Growth

6. Juli 20226. Juli 2022 Firma ProtaGeneAllgemeinanalysis, analytics, drug, gene, genewerk, lab, labs, new, project, protagene, protein, storage, therapy, vector, with

ProtaGene is thrilled to announce the planned opening of our brand-new, state-of-the-art lab and office headquarters in the Burlington BioCenter, located in Boston’s rapidly growing biotechnology hub. Our expanded footprint is designed to enable new capabilities required to advance today’s Mehr

Autor: Firma ProtaGene